放射性标记Pentixafor/Pentixather用于靶向诊疗肿瘤进展  

Progresses of radiolabeled Pentixafor/Pentixather applied in targeted diagnosis and treatment of tumors

作　　者：王敏 马佼 刘李乙 张春银 WANG Min;MA Jiao;LIU Liyi;ZHANG Chunyin(Department of Nuclear Medicine,Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province,AcademicianWorkstation of Sichuan Province,the Affiliated Hospital of Southwest Medical University,Luzhou 646000,China)

机构地区：[1]西南医科大学附属医院核医学科,核医学与分子影像学四川省重点实验室,四川省院士(专家)工作站,四川泸州646000

出　　处：《中国医学影像技术》2023年第5期785-788,共4页Chinese Journal of Medical Imaging Technology

摘　　要：肿瘤细胞表面多过度表达趋化因子受体4(CXCR4),后者在肿瘤发生、发展和转移等各环节中具有重要作用,为靶向诊疗肿瘤的重要靶点。Pentixafor是由基质细胞衍生因子-1合成的环五肽类似物,为CXCR4配体,可用于合成放射性共轭物^(68)Ga-Pentixafor,而Pentixather为其治疗用化合物。近年来,放射性标记Pentixafor/Pentixather在诊断和治疗肿瘤方面展现出重要作用。本文就放射性标记Pentixafor/Pentixather在靶向诊疗肿瘤中的应用进展进行综述。Chemokine receptor 4(CXCR4)is overexpressed on the surface of most tumor cells,playing an important role in the occurrence,development and metastasis of tumors,hence being important for targeted diagnosis and treatment of tumors.Pentixafor is a cyclic pentapeptide analogue synthesized by stromal cell-derived factor 1,also is a ligand of CXCR4,which can be used to synthesize radioactive conjugate ^(68)Ga-Pentixafor.Pentixather is the corresponding therapeutic compound of ^(68)Ga-Pentixafor.In recent years,radiolabeled Pentixafor/Pentixather had played an important role in diagnosis and treatment of tumors.The progresses of radiolabeled Pentixafor/Pentixather applied in targeted diagnosis and treatment of tumors were reviewed in this article.

关 键 词：肿瘤 受体 趋化因子 分子靶向治疗 

分 类 号：R74[医药卫生—神经病学与精神病学] R817.4[医药卫生—临床医学]